What's new? Log in Free sign up

ProPhase Labs (PRPH) News and press releases

Company Profile

News

From Benzinga Pro

ProPhase Labs FY EPS $1.02 Misses $1.15 Estimate, Sales $122.65M Beat $121.33M Estimate

ProPhase Labs (NASDAQ:PRPH) reported quarterly earnings of $1.02 per share which missed the analyst consensus estimate of $1.15 by 11.3 percent. This is a 155 percent increase over earnings of $0.40 per share from the

Earnings Scheduled For March 28, 2023

Companies Reporting Before The Bell • Futu Holdings (NASDAQ:FUTU) is expected to report quarterly earnings at $0.70 per share on revenue of $237.12 million.

ProPhase Labs Earnings Preview

HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $15 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $15 price target.

Prophase Labs Collaboration With mProbe And Dr. Christopher Hartley Of Mayo Clinic For The Continued Development Of Its BE-smart Esophageal Pre-cancer Diagnostic Screening Test

News, Health Care, Contracts, General

mProbe plans to continue testing specimens provided by the Mayo Clinic in the first quarter of 2023. ProPhase Labs intends to pursue initial commercialization of the BE-Smart test as a laboratory-developed

HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $15 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $15 price target.

ProPhase Labs Announces Plans To Initiate Clinical Trial Of Equivir, Goal To Launch Commercially In Q4 2023

Biotech, News, FDA, General

ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase"), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly-owned subsidiary, ProPhase BioPharma, Inc. (PBIO), is

ProPhase Labs Esophageal Cancer Early Detection Test (BE-smart) Featured in Peer-Reviewed Article in the International Journal of Molecular Science

News, Health Care, General

To date, the BE-Smart test has been tested on over 200 human samples by mProbe Inc, a precision health and medicine company utilizing clinical proteomics in the oncology space, and has shown greater

HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $15 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $15 price target.

Prophase Labs' Prophase Labs Will Acquiring New Equipment Which Is Expected To Double Its Current Capacity For Pouch Packaging By Q2 Of 2023. Pharmaloz Is Also Planning For Expansion Of Its Lozenge Manufacturing Business

News, Health Care, General

Altogether, these expansion initiatives are expected to lead to a 200% increase in capacity for 2024 as compared to 2022. It is currently expected that the Pharmaloz expansion will be funded entirely from

HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $15 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $15 price target.

ProPhase Labs Expects To Initiate Preclinical Requirements For Investigational New Drug Application Submission For Linebacker-1 Cancer Co-Therapy Program In Q4 2023

ProPhase expects to initiate the preclinical requirements for investigational new drug (IND) application submission in the fourth quarter of 2023. These requirements include: Study Protocol Design: select

A Look Into Healthcare Sector Value Stocks

12 Health Care Stocks Moving In Wednesday's After-Market Session

5 Value Stocks In The Healthcare Sector

Press releases

From Benzinga Pro

ProPhase Labs Announces Record Financial Results for the year ended December 31, 2022

Company highlights key strategic initiatives to grow underlying value in 2023 and beyond Company announces it is in strategic discussions to develop BE-Smart cancer test globally Company to hold a conference call

Impact Biomedical Preparing A Potential Spinoff — What Does This Mean For Investors Of Holding Company DSS, Inc (NYSE American: DSS)?

West Henrietta, NY--News Direct--By Ernest Dela Aglanu, BenzingaImpact Biomedical, a biotechnology company focused on developing innovative treatments for a wide range of diseases and conditions and one of the key

ProPhase Labs to Host 2022 Year End Financial Results Conference Call on Tuesday, March 28, 2023 at 11:00 a.m. Eastern Time

GARDEN CITY, NY, March 21, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on Tuesday, March 28,

ProPhase Labs' Nebula Genomics Subsidiary Introduces Lowest Ever NGS Pricing of $249 for its Whole Genome Sequencing DNA Test

Company Provides Update on Significant Progress at Nebula Genomics Subsidiary Garden City, NY, March 07, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase"), a growth oriented and diversified

DSS Announces Letter to Shareholders

Penny Stocks, Press Releases

CEO Highlights Business Plan including Spin-Offs

ProPhase Labs Announces Collaboration with mProbe, Inc. and Mayo Clinic for the Continuing Development of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test

Company Outlines BE-Smart Test Roadmap for Commercialization in the U.S. Company in Early Stages of Exploring Development for Commercialization in Other Countries Garden City, NY, March 01, 2023 (GLOBE

ProPhase Labs Announces Plans to Initiate Clinical Trial of Equivir (OTC)

Goal to launch commercially in Q4 2023 Garden City, NY, Feb. 22, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase"), a growth oriented and diversified diagnostics, genomics and biotech company,

ProPhase Labs Esophageal Cancer Early Detection Test (BE-smart) Featured in Peer-Reviewed Article in the International Journal of Molecular Science

Garden City, NY, Feb. 16, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its flagship diagnostic test,

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.